165 related articles for article (PubMed ID: 37659201)
1. HDAC11: A novel target for improved cancer therapy.
Liu Y; Tong X; Hu W; Chen D
Biomed Pharmacother; 2023 Oct; 166():115418. PubMed ID: 37659201
[TBL] [Abstract][Full Text] [Related]
2. HDAC11: a rising star in epigenetics.
Liu SS; Wu F; Jin YM; Chang WQ; Xu TM
Biomed Pharmacother; 2020 Nov; 131():110607. PubMed ID: 32841898
[TBL] [Abstract][Full Text] [Related]
3. The role of HDAC11 in obesity-related metabolic disorders: A critical review.
Yang H; Chen L; Sun Q; Yao F; Muhammad S; Sun C
J Cell Physiol; 2021 Aug; 236(8):5582-5591. PubMed ID: 33481312
[TBL] [Abstract][Full Text] [Related]
4. Unraveling HDAC11: Epigenetic orchestra in different diseases and structural insights for inhibitor design.
Khatun S; Prasad Bhagat R; Dutta R; Datta A; Jaiswal A; Halder S; Jha T; Amin SA; Gayen S
Biochem Pharmacol; 2024 Jul; 225():116312. PubMed ID: 38788962
[TBL] [Abstract][Full Text] [Related]
5. HDAC11 inhibition disrupts porcine oocyte meiosis via regulating α-tubulin acetylation and histone modifications.
Huang R; Sui L; Fu C; Zhai Y; Dai X; Zhang S; Li Z
Aging (Albany NY); 2021 Mar; 13(6):8849-8864. PubMed ID: 33742608
[TBL] [Abstract][Full Text] [Related]
6. Histone Deacetylase 11 Is an ε-N-Myristoyllysine Hydrolase.
Moreno-Yruela C; Galleano I; Madsen AS; Olsen CA
Cell Chem Biol; 2018 Jul; 25(7):849-856.e8. PubMed ID: 29731425
[TBL] [Abstract][Full Text] [Related]
7. HDAC11 is a regulator of diverse immune functions.
Yanginlar C; Logie C
Biochim Biophys Acta Gene Regul Mech; 2018 Jan; 1861(1):54-59. PubMed ID: 29222071
[TBL] [Abstract][Full Text] [Related]
8. HDAC11 is a novel drug target in carcinomas.
Deubzer HE; Schier MC; Oehme I; Lodrini M; Haendler B; Sommer A; Witt O
Int J Cancer; 2013 May; 132(9):2200-8. PubMed ID: 23024001
[TBL] [Abstract][Full Text] [Related]
9. Development and Pharmacochemical Characterization Discover a Novel Brain-Permeable HDAC11-Selective Inhibitor with Therapeutic Potential by Regulating Neuroinflammation in Mice.
Bai P; Liu Y; Yang L; Ding W; Mondal P; Sang N; Liu G; Lu X; Ho TT; Zhou Y; Wu R; Birar VC; Wilks MQ; Tanzi RE; Lin H; Zhang C; Li W; Shen S; Wang C
J Med Chem; 2023 Dec; 66(23):16075-16090. PubMed ID: 37972387
[TBL] [Abstract][Full Text] [Related]
10. HDAC11: a multifaceted histone deacetylase with proficient fatty deacylase activity and its roles in physiological processes.
Núñez-Álvarez Y; Suelves M
FEBS J; 2022 May; 289(10):2771-2792. PubMed ID: 33891374
[TBL] [Abstract][Full Text] [Related]
11. HDAC11 promotes meiotic apparatus assembly during mouse oocyte maturation via decreasing H4K16 and α-tubulin acetylation.
Sui L; Zhang S; Huang R; Li Z
Cell Cycle; 2020 Feb; 19(3):354-362. PubMed ID: 31910069
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase 11 suppresses p53 expression in pituitary tumor cells.
Wang W; Fu L; Li S; Xu Z; Li X
Cell Biol Int; 2017 Dec; 41(12):1290-1295. PubMed ID: 28782861
[TBL] [Abstract][Full Text] [Related]
14. Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2.
Bora-Singhal N; Mohankumar D; Saha B; Colin CM; Lee JY; Martin MW; Zheng X; Coppola D; Chellappan S
Sci Rep; 2020 Mar; 10(1):4722. PubMed ID: 32170113
[TBL] [Abstract][Full Text] [Related]
15. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma.
Mostofa A; Distler A; Meads MB; Sahakian E; Powers JJ; Achille A; Noyes D; Wright G; Fang B; Izumi V; Koomen J; Rampakrishnan R; Nguyen TP; De Avila G; Silva AS; Sudalagunta P; Canevarolo RR; Siqueira Silva MDC; Alugubelli RR; Dai HA; Kulkarni A; Dalton WS; Hampton OA; Welsh EA; Teer JK; Tungesvik A; Wright KL; Pinilla-Ibarz J; Sotomayor EM; Shain KH; Brayer J
JCI Insight; 2021 Dec; 6(24):. PubMed ID: 34793338
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer.
Parbin S; Kar S; Shilpi A; Sengupta D; Deb M; Rath SK; Patra SK
J Histochem Cytochem; 2014 Jan; 62(1):11-33. PubMed ID: 24051359
[TBL] [Abstract][Full Text] [Related]
17. HDAC11 Regulates Glycolysis through the LKB1/AMPK Signaling Pathway to Maintain Hepatocellular Carcinoma Stemness.
Bi L; Ren Y; Feng M; Meng P; Wang Q; Chen W; Jiao Q; Wang Y; Du L; Zhou F; Jiang Y; Chen F; Wang C; Tang B; Wang Y
Cancer Res; 2021 Apr; 81(8):2015-2028. PubMed ID: 33602787
[TBL] [Abstract][Full Text] [Related]
18. Utilization of AlphaFold models for drug discovery: Feasibility and challenges. Histone deacetylase 11 as a case study.
Baselious F; Robaa D; Sippl W
Comput Biol Med; 2023 Dec; 167():107700. PubMed ID: 37972533
[TBL] [Abstract][Full Text] [Related]
19. Histone/protein deacetylase 11 targeting promotes Foxp3+ Treg function.
Huang J; Wang L; Dahiya S; Beier UH; Han R; Samanta A; Bergman J; Sotomayor EM; Seto E; Kozikowski AP; Hancock WW
Sci Rep; 2017 Aug; 7(1):8626. PubMed ID: 28819166
[TBL] [Abstract][Full Text] [Related]
20. HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.
Yue L; Sharma V; Horvat NP; Akuffo AA; Beatty MS; Murdun C; Colin C; Billington JMR; Goodheart WE; Sahakian E; Zhang L; Powers JJ; Amin NE; Lambert-Showers QT; Darville LN; Pinilla-Ibarz J; Reuther GW; Wright KL; Conti C; Lee JY; Zheng X; Ng PY; Martin MW; Marshall CG; Koomen JM; Levine RL; Verma A; Grimes HL; Sotomayor EM; Shao Z; Epling-Burnette PK
Blood; 2020 Jan; 135(3):191-207. PubMed ID: 31750881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
